Larvol Delta - The-Company-is-reevaluating-the-timing-and-scope-of-its-clinical-development-programs

ozuriftamab vedotin (BA3021) - BioAtla

BA3182 - BioAtla

https://www.globenewswire.com/news-release/2026/03/31/3266019/0/en/BioAtla-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights.html

Mar 31, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next